AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/04/22

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences. H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday,...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

Aurinia Pharmaceuticals (NASDAQ:AUPH) is trading ~2.5% higher in the pre-market after Oppenheimer raised its recommendation on the stock to Outperform from Perform. The price target of $31 per share implies a premium of ~47.8% to the last close. While the upgrade was based on valuat...

Aurinia Pharmaceuticals rose 2.7%, near highs of the day, after a report that the biotech company is said to close deciding on a preferred bidder in its strategic review Aurinia's board it said to be near a decision to enter exclusive talks with one of the parties that expressed interest...

After three days of strong gains, Wall Street looks ready to take a bit of a break. Thursday morning brought modest pullbacks in most major stock indexes, as market participants turn their attention to economic data over the next couple of days to guide their longer-term strategies. As of 8...

Ensysce Biosciences (NASDAQ:ENSC) +83%. Inspira Technologies (NASDAQ:IINN) +59%. American Virtual Cloud Technologies (NASDAQ:AVCT) +29% announces significant projected revenue growth of Kandy, its cloud communications platform. Siyata Mobile (NASDAQ:SYTA) +28%. Digital Brands (NASDAQ:DBG...

Aurinia Pharmaceuticals (NASDAQ:AUPH) perks up 6.8% premarket after announcing positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of Lupkynis (voclosporin) for the treatment of adults with active lupus nephritis (LN), a ser...

- Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy - - Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroid...

On Tuesday, Bristol-Myers Squibb (NYSE:BMY) reached a 52-week low of $53.22. Unlike most of its large U.S. pharmaceutical company peers which are doing well in 2021, its shares are down 9.2% for the year. While Bristol's Q3 2021 revenue and profit beat Street expectations in October...

Wall Street's volatile week continued on Thursday, with stocks bouncing back after their recent losses. The rebound included a strong performance from a collection of retail names, as investors found hope in a handful of earnings reports that higher costs wouldn't necessarily obliterate margi...